Also trades as: 4565.T (JPX) · $vol 7M
SOLTF OTC
Nxera Pharma Co., Ltd.
1W: -6.3%
1M: +56.1%
3M: +22.8%
YTD: +42.7%
1Y: +22.2%
3Y: -47.9%
5Y: -41.0%
$7.82
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$2.7B
+65.4% ▲
Capital Expenditures
$448M
+70.8% ▲
5Y CAGR: +33.7%
Free Cash Flow
-$3.1B
+66.3% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$11.8B
+29.7% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $433M | $1.1B | -$7.2B | -$4.7B | -$12.5B |
| Depreciation & Amort. | $1.3B | $1.3B | $2.5B | $4.0B | $4.4B |
| Stock-Based Comp. | $713M | $700M | $870M | $1.4B | $0 |
| Change in Working Capital | -$1.8B | $5.3B | $1.6B | -$6.0B | -$1.6B |
| Other Non-Cash Items | $3.8B | -$790M | -$3.0B | -$2.4B | $7.1B |
| Operating Cash Flow | $7.1B | $10.0B | -$5.3B | -$7.7B | -$2.7B |
| — Investing Activities — | |||||
| Capital Expenditures | -$201M | -$303M | -$804M | -$526M | -$626M |
| Acquisitions (Net) | $206M | $137M | -$62.9B | $379M | $0 |
| Investment Purchases | -$206M | $26M | $0 | $0 | -$3.9B |
| Investment Sales | $206M | $1.2B | $0 | $0 | $6.0B |
| Other Investing | $273M | -$26M | -$46M | -$4.6B | $4.0B |
| Investing Cash Flow | $278M | $1.0B | -$63.8B | -$4.8B | $5.4B |
| — Financing Activities — | |||||
| Net Debt Issuance | $10.9B | $0 | $38.9B | -$6.0B | -$5.8B |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$374M | -$4.9B | -$512M | -$904M | -$10.2B |
| Financing Cash Flow | $11.1B | -$4.9B | $48.3B | -$6.9B | -$16.0B |
| Net Change in Cash | $20.1B | $6.5B | -$17.5B | -$16.8B | -$11.8B |
| Cash End of Period | $60.1B | $66.6B | $49.1B | $32.3B | $20.4B |
| Free Cash Flow | $6.9B | $9.6B | -$6.1B | -$9.3B | -$3.1B |